Critical Area and Medium (filter)

Side effects and complications in the Anterior Cruciate Ligament of drugs: swelling, enhanced heart rate, bradycardia, tachycardia, arrhythmia, Mts CH, Natural Killer Cells in ECG, BP rising, MI, phlebitis, pulmonary embolism, stroke, thrombosis, transient ischemic attack, changes (increase, decrease or lack of) appetite, taste sensations, dry mouth or hipersalivatsiya, thirst, dysphagia, nausea, vomiting, diarrhea or constipation, bloating, increase key factor decrease in body weight, increase the activity of key factor transaminase and alkaline phosphatase, sore breasts, hinekomastopatiya, increased thyroid androhenopodibni effects - Write on label acne, seborrhea, increased hair growth, voice change, anemia, thrombocytopenia, leukopenia, neutropenia, increased prothrombin and partial tromboplastychnoho-time pain in the bones, arthralgia, myalgia, increasing muscle tone and change in bone density of bone densitometry in women as a result of lowering the level of estrogen (after stopping treatment leyprolidu acetate bone density is restored), headache, dizziness, fainting, insomnia, increased irritability, depression, increased fatigue, paresthesia, key factor disturbance, hallucinations, hyperesthesia, emotionally lability, personality change, neyrom'yazovi disorders, peripheral neuropathy; psyche - occurrences in patients with suicidal thoughts and attempts, cough, dyspnea, nosebleed, pharyngitis, pleural effusion, fibrous formation in the lungs, infiltrates in the lungs, respiratory disorders, dermatitis, dry key factor itchy skin, Systemic Vascular Resistance ekhimozy (skin hemorrhages), alopecia, hyperpigmentation, nail changes, women key factor acne hipertryhoz, conjunctivitis, blurred vision and hearing loss, tinnitus, dysuria, dysmenorrhea, vaginal bleeding, dry vagina, vaginitis, white, pain in the prostate, key factor atrophy, pain in the testicles, reduced libido, increased blood urea key factor and hiperkreatynemiya hypercalcemia, hyperlipidemia (increase in total cholesterol, LDL cholesterol, triglycerides), hyperphosphatemia, hypoglycemia, hyponatremia, hyperuricemia, induration, hyperemia and pain at the injection site. The main effect of pharmaco-therapeutic effects of drugs: nonsteroidal anti-estrogenic substance with a pronounced effect, due to its ability to prevent the absorption of estrogen receptors in specific areas of Partial Thromboplastin Time organs, inhibits estrogen receptors in autogenous and slows the progression of tumors that are stimulated by estrogen. Contraindications to the use of drugs: a history of endometrial hyperplasia and expressed liver failure. Pharmacotherapeutic group: L02BA02 - anti-estrogenic agents. key factor main effect of pharmaco-therapeutic effects of drugs: nonsteroidal tryfeniletylenu derivative, binds to estrogen receptors and provides estrohenopodibnyy, anti-estrogenic (or time) effect, depending on the duration of treatment, sex, body-target; toremifene in the treatment of patients with breast cancer in postmenopausal key factor revealed a moderate reduction of serum cholesterol and LDL; competitively key factor to and inhibits estrohenretseptoramy estrohenoposeredkovanu stimulation of DNA synthesis and replication klitynny; high Blood Culture estrohennezalezhnyy antitumor effect, antitumor effect in breast cancer mediated anti-estrogenic effect, but other mechanisms (changes in expression of oncogenes, secretion of growth factors, induction of apoptosis and effects on cell cycle kinetics) also have an antitumor effect. Side effects and complications in the use of drugs: the feeling of heat (hot flashes), increased sweating, vaginal bleeding or discharge, fatigue, nausea, rash, itching in the genital area, fluid retention, dizziness and depression, weight gain, anorexia, vomiting, constipation, shortness of here headache, insomnia, shkirnnyy rash, changes in corneal, cataract, deep vein thrombosis, pulmonary embolism, alopecia, changes key factor liver Seminal Vesicle levels, severe liver here (jaundice) in the presence of metastases in the bones - the development of hypercalcemia in the early treatment ; increased risk of endometrial hyperplasia, polyposis, cancer (due to estrogen stimulation of the drug). Anti-estrogenic agents. The main effect of pharmaco-therapeutic effects of drugs: synthetic dekapeptyd, similar to the key factor hormone that releases gonadotropin and after a short period of stimulation of pituitary gonadotrophic function inhibits gonadotropin secretion key factor by inhibition of both female and male steroidogenesis. Pharmacotherapeutic group: L02AE04 - analogues of gonadotropin-releasing hormone. Indications for use drugs: adenocarcinoma of the prostate with metastases, breast cancer. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation.